Spectrum Pharmaceuticals Inc

Type: Public
On the web: http://www.spectrumpharm.com
Employees: 84
Employee growth: 37.7%

Spectrum Pharmaceuticals sees a rainbow of opportunities in its drug development pipeline. The drug firm, which focuses on anti-cancer therapies, won FDA approval in 2008 for its injectable LEVOleucovorin for use with some osteosarcoma patients; the drug reduces the toxic effects of a certain type of chemotherapy. Another investigational candidate, EOquin, is being studied as a bladder cancer treatment. Spectrum has licensed global rights to a third anti-cancer compound, satraplatin, to GPC Biotech. Additionally, in 2008 the company sold to Par Pharmaceutical its share of profits for the authorized generic of GlaxoSmithKline's migraine drug Imitrex; Par had been Spectrum's marketing partner for the drug.

Key numbers for fiscal year ending December, 2008:
Sales: $28.7M
One year growth: 274.4%
Net income: ($15.5)M

Officers:
Chairman, President, and CEO: Rajesh C Shrotriya
VP Finance and Secretary: Shyam K. Kumaria
VP Sales and Marketing: George C. Uy

Competitors:
Abbott Labs
Bristol-Myers Squibb
Eli Lilly